S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
NASDAQ:IMPL

Impel Pharmaceuticals - IMPL Stock Forecast, Price & News

$3.59
+0.15 (+4.36%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.36
$3.60
50-Day Range
$2.59
$4.10
52-Week Range
$2.52
$10.75
Volume
8,007 shs
Average Volume
24,823 shs
Market Capitalization
$85.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Impel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
491.9% Upside
$21.25 Price Target
Short Interest
Healthy
1.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of Impel Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.65) to ($2.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

448th out of 1,055 stocks

Pharmaceutical Preparations Industry

217th out of 519 stocks


IMPL stock logo

About Impel Pharmaceuticals (NASDAQ:IMPL) Stock

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IMPL Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
IMPL Impel Pharmaceuticals Inc.
Impel Dips on Q2 Numbers
See More Headlines
Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IMPL Company Calendar

Last Earnings
11/14/2022
Today
1/28/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMPL
Fax
N/A
Employees
129
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.25
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+317.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-76,540,000.00
Net Margins
-1,313.87%
Pretax Margin
-1,313.84%

Debt

Sales & Book Value

Annual Sales
$670,000.00
Book Value
$2.28 per share

Miscellaneous

Free Float
22,243,000
Market Cap
$85.23 million
Optionable
Not Optionable
Beta
-0.62

Key Executives

  • Mr. Adrian AdamsMr. Adrian Adams (Age 71)
    Chairman & CEO
    Comp: $956.42k
  • Dr. John D. Hoekman Ph.D. (Age 41)
    Co-Founder and Chief Technology & Devel. Officer
  • Dr. John H. Leaman M.D. (Age 49)
    Chief Financial & Bus. Officer
    Comp: $964.37k
  • Mr. Leonard S. Paolillo (Age 43)
    Chief Commercial Officer
    Comp: $496.7k
  • Ms. Jennifer L. Berman
    VP of Marketing
  • Ms. Patty Billingsley
    VP of Sales
  • Ms. Sarah Wille
    VP of HR
  • Dr. Stephen Bevan Shrewsbury M.B. Ch.B. (Age 65)
    M.D., Chief Medical Officer
  • Dr. Lynn C. Gold Ph.D. (Age 65)
    Sr. VP of Regulatory
  • Mr. Scott Youmans (Age 55)
    Sr. VP of Technical Operations













IMPL Stock - Frequently Asked Questions

Should I buy or sell Impel Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Impel Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IMPL shares.
View IMPL analyst ratings
or view top-rated stocks.

What is Impel Pharmaceuticals' stock price forecast for 2023?

2 equities research analysts have issued twelve-month price targets for Impel Pharmaceuticals' stock. Their IMPL share price forecasts range from $5.00 to $40.00. On average, they predict the company's share price to reach $21.25 in the next twelve months. This suggests a possible upside of 491.9% from the stock's current price.
View analysts price targets for IMPL
or view top-rated stocks among Wall Street analysts.

How have IMPL shares performed in 2023?

Impel Pharmaceuticals' stock was trading at $3.75 at the beginning of the year. Since then, IMPL stock has decreased by 4.3% and is now trading at $3.59.
View the best growth stocks for 2023 here
.

When is Impel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our IMPL earnings forecast
.

How were Impel Pharmaceuticals' earnings last quarter?

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) issued its quarterly earnings data on Monday, November, 14th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by $0.44. The company earned $3.08 million during the quarter, compared to analyst estimates of $5.16 million. Impel Pharmaceuticals had a negative trailing twelve-month return on equity of 701.26% and a negative net margin of 1,313.87%.

When did Impel Pharmaceuticals IPO?

(IMPL) raised $80 million in an IPO on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO.

What is Impel Pharmaceuticals' stock symbol?

Impel Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMPL."

Who are Impel Pharmaceuticals' major shareholders?

Impel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Mcdonald Partners LLC (0.05%). Insiders that own company stock include Adrian Adams, Global Strategic Fund I Venbio, Timothy S Nelson and Vivo Capital Viii, Llc.
View institutional ownership trends
.

How do I buy shares of Impel Pharmaceuticals?

Shares of IMPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Impel Pharmaceuticals' stock price today?

One share of IMPL stock can currently be purchased for approximately $3.59.

How much money does Impel Pharmaceuticals make?

Impel Pharmaceuticals (NASDAQ:IMPL) has a market capitalization of $85.23 million and generates $670,000.00 in revenue each year. The company earns $-76,540,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis.

How many employees does Impel Pharmaceuticals have?

The company employs 129 workers across the globe.

How can I contact Impel Pharmaceuticals?

The official website for the company is www.Impelnp.com. The company can be reached via phone at 206-568-1466.

This page (NASDAQ:IMPL) was last updated on 1/28/2023 by MarketBeat.com Staff